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Available online 3 May 2016Vascular calciﬁcation, which is common in the elderly and in patients with atherosclerosis, diabetes and chronic
renal disease, increases the risk of cardiovascular morbidity and mortality. It is a complex, active and highly reg-
ulated cellular process that resembles physiological bone formation. It has previously been established that phar-
macological doses of glucocorticoids facilitate arterial calciﬁcation. However, the consequences for vascular
calciﬁcation of endogenous glucocorticoid elevation have yet to be established. Glucocorticoids (cortisol, cortico-
sterone) are released from the adrenal gland, but can also be generated within cells from 11-keto metabolites of
glucocorticoids (cortisone, 11-dehydrocorticosterone [11-DHC]) by the enzyme, 11β-hydroxysteroid dehydro-
genase type 1 (11β-HSD1). In the current studywe hypothesized that endogenous glucocorticoids facilitate vas-
cular smoothmuscle cell (VSMC) calciﬁcation and investigated the receptor-mediatedmechanism underpinning
this process.
In vitro studies revealed increased phosphate-induced calciﬁcation in mouse VSMCs following treatment for
7 days with corticosterone (100 nM; 7.98 fold; P b 0.01), 11-DHC (100 nM; 7.14 fold; P b 0.05) and dexametha-
sone (10 nM; 7.16 fold; P b 0.05), a synthetic glucocorticoid used as a positive control. Inhibition of 11β-HSD iso-
enzymes by 10 μMcarbenoxolone reduced the calciﬁcation induced by 11-DHC (0.37 fold compared to treatment
with 11-DHC alone; P b 0.05). The glucocorticoid receptor (GR) antagonistmifepristone (10 μM)had no effect on
VSMC calciﬁcation in response to corticosterone or 11-DHC. In contrast, the mineralocorticoid receptor (MR) an-
tagonist eplerenone (10 μM) signiﬁcantly decreased corticosterone- (0.81 fold compared to treatment with cor-
ticosterone alone; P b 0.01) and 11-DHC-driven (0.64 fold compared to treatment with 11-DHC alone; P b 0.01)
VSMC calciﬁcation, suggesting this glucocorticoid effect is MR-driven and not GR-driven. Neither corticosterone
nor 11-DHC altered the mRNA levels of the osteogenic markers PiT-1, Osx and Bmp2. However, DAPI staining of
pyknotic nuclei andﬂow cytometry analysis of surface AnnexinV expression showed that corticosterone induced
apoptosis in VSMCs.
This study suggests that in mouse VSMCs, corticosterone acts through the MR to induce pro-calciﬁcation effects,
and identiﬁes 11β-HSD-inhibition as a novel potential treatment for vascular calciﬁcation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Vascular calciﬁcation is a marker of increased cardiovascular disease
risk in aging, including in diabetes, atherosclerosis and chronic kidney
disease (CKD) [23,50]. The etiology of mineral accumulation within
the vasculature sharesmany similaritieswith that of bone formation. In-
deed, several studies have reported that vascular smooth muscle cells
(VSMCs), the predominant cell type involved in vascular calciﬁcation,
can undergo phenotypic transition to osteoblastic, chondrocytic and.2016.07.003.
yal (Dick) School of Veterinary
lothian EH25 9RG, UK.
cRae).
. This is an open access article underosteocytic cells in a calciﬁed environment [16,49]. Furthermore, phos-
phate accelerates this trans-differentiation process, with the loss of
characteristic smooth muscle markers and the increased expression of
osteoblastic markers (e.g. Osterix, PiT-1 and BMP2) [28,31,51]. Vascular
calciﬁcation can also proceed through mechanisms involving the recip-
rocal loss of recognized calciﬁcation inhibitors including inorganic pyro-
phosphate (PPi), fetuin A and Matrix Gla Protein [16,25,30,36].
Physiological glucocorticoids — primarily cortisol in humans and
corticosterone in rats and mice — are steroid hormones produced by
the adrenal cortex. Local glucocorticoid action on target tissues is
determined by intracellular metabolism by the two isozymes of 11β-
hydroxysteroid dehydrogenase (11β-HSD)which catalyze interconver-
sion of active cortisol and corticosterone with inert cortisone and 11-
dehydrocorticosterone [11]. 11β-HSD type 1, a predominant reductasethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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thus amplifying cellular action. 11β-HSD2 is a high-afﬁnity dehydroge-
nase that inactivates glucocorticoids [4]. Both isozymes of 11HSD are
modestly expressed in the blood vessel wall, suggesting that they can
inﬂuence vascular function by regulating local availability of active glu-
cocorticoids [11].
In the absence of 11β-HSD2, endogenous glucocorticoids can bind to
themineralocorticoid receptor (MR) aswell as the glucocorticoid recep-
tor (GR) [37]. Both MR and GR belong to the same nuclear hormone re-
ceptor superfamily, and share high sequence identity. MR has higher
afﬁnity for glucocorticoids than GR, and both receptors are expressed
in the cells of the vasculature [10]. Glucocorticoids can activate the MR
in VSMCs (11β-HSD2 is not expressed here), inducing pathways that
are central to cell proliferation and differentiation [27].
Glucocorticoids are frequently permissive, co-operative or synergis-
tic [48]. Indeed a permissive role of glucocorticoids in triggering cell
transdifferentiation has previously been established in the conversion
of pancreatic cells into hepatocytes [38]. Furthermore, glucocorticoids
exert complex actions on calcium mobilisation and bone metabolism,
regulating bone resorption and formation [13], intestinal calcium
absorption and renal calcium excretion [8]. Therefore it is essential to
establish the consequences for vascular calciﬁcation of endogenous
glucocorticoid elevation given the high circulating calcium levels com-
monly observed in patients with this pathology [2].
Dexamethasone, a potent synthetic glucocorticoid which is pri-
marily active at the GR, induces an osteoblastic differentiation path-
way in many different mesenchymal-derived cell types in vitro [1,5,
47], including VSMCs [29,39]. Whilst the established pro-Fig. 1. Dexamethasone, corticosterone and 11-DHC all glucocorticoids induce VSMC calciﬁcat
dehydrocorticosterone (11DHC; ﬁlled bar) (1–100 nM) in the presence of standard and charc
presence or absence of 11DHC (100 nM) on calcium deposition in VSMCs cultured in hig
quantitative HCL leaching (μg/mg protein) (n= 6). Results are presented as mean ±S.E.M. *Pcalciﬁcation actions of dexamethasone on VSMCs [18,29] are pre-
sumed to be mediated via GR, plausibly endogenous corticosteroids
may modulate VSMC calciﬁcation via MR. This is therapeutically im-
portant to ascertain, as vascular calciﬁcation is independently correlat-
ed with adverse cardiac events [50], and MR antagonism is highly
successful in reducingmortality in heart failure [45]; aldosterone antag-
onists such as spironolactone and eplerenone have been shown to im-
prove cardiovascular outcomes and prevent ischaemic events in
cardiovascular patients [32,33]. Corticosterone has been shown to in-
duce rapidMR signaling in VSMCs that involves mitogen-activated pro-
tein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-
dependent pathways, suggesting that glucocorticoids may contribute
to vascular disease via MR receptor signaling [27]. Recent studies have
shown that aldosterone-induced activation of MR promotes osteoblas-
tic differentiation and calciﬁcation of VSMCs [15] through a mechanism
involving the stimulation of spironolactone-sensitive, PiT-1 dependent
signaling [46].
An additional level of control over endogenous corticosteroid action
is provided by the HSD isoenzymes, whose role in vascular calciﬁcation
has yet to be elucidated. The induction of local glucocorticoid generation
through increased 11β-HSD1 expression (N10 fold) and activity (N4
fold) by inﬂammatory cytokines and glucocorticoids is well document-
ed in ﬁbroblasts and osteoblasts [19,43], which both have the capacity
to calcify [3,42].
It is therefore essential to establish the consequences for vascular
calciﬁcation of endogenous glucocorticoid elevation and potential strat-
egies for inhibition of calciﬁcation. The aims of this studywere to under-
take in vitromurine VSMC calciﬁcation studies to investigate both theion. Effect of (A) dexamethasone (1–100 nM), (B, C) corticosterone (white bar) and 11-
oal-stripped fetal bovine serum (FBS) respectively and (D) carbenoxolone (10 μM) in the
h phosphate (Pi) (3 mM Pi) for 7 days, as determined by alizarin red staining and/or
b 0.05; **P b 0.01; ***P b 0.001 compared with corresponding 0 nM treatment.
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corticosterone-induced calciﬁcation.
2. Materials and methods
2.1. Mice
All animal experiments were performed under UK Home Ofﬁce li-
censed approval in accordance with Directive 2010/63/EU of the
European Parliament and were maintained in accordance with Home
Ofﬁce guidelines for the care and use of laboratory animals. C57BL/6
mice were supplied by Charles River Laboratories (Harlow, Essex, UK).
2.2. Preparation of VSMCs
Mice were euthanized by cervical dislocation. Primary murine
VSMCs were isolated as described [24]. Brieﬂy, after removal of the ad-
ventitia, the aorta was opened to expose the endothelial layer under a
dissection microscope. Tissues from eight animals were pooled and in-
cubated with 1 mg ml−1 trypsin (Invitrogen, Paisley, UK) for 10 min
in order to enable the removal of any remaining adventitia and endo-
thelium through further dissection. Following overnight incubation at
37 °C in a humidiﬁed atmosphere of 95% air/5% CO2 in “growthFig. 2. Endogenous glucocorticoids induce VSMC calciﬁcation through themineralocorticoid rec
of corticosterone (100 nM) and (C) mifepristone (10 μM) and (D) eplerenone (10 μM) in the p
cultured in high phosphate (Pi) (3 mM Pi) for 7 days, as determined by quantitative HCL
**P b 0.01; ***P b 0.001.medium” (α-MEM supplemented with 10% fetal bovine serum and 1%
gentamicin, all from Invitrogen), tissues were digested with 425 U/ml
collagenase type II (Worthington Biochemical Corporation, Lakewood,
USA) for 5 h. Cell suspensions were centrifuged at 2000 g for 5 min.
The cell pellet was washed and resuspended in growthmedium. Isolat-
ed VSMCs were passaged in growthmedium twice in T25 tissue culture
ﬂasks (Greiner Bio-one, GmbH, Frickenhausen, Baden-Wurttemberg,
Germany) coated with 0.25 μg/cm2 laminin (Sigma, Poole, UK) to pro-
mote maintenance of the contractile differentiation state [17]. VSMCs
were subsequently seeded at a density of 1.5 × 104/cm2 in 12-well
plates.
2.3. Induction of VSMC calciﬁcation
In vitro calciﬁcation of VSMCs was induced by culturing cells in
growth medium containing 3 mM inorganic phosphate (a mixture of
NaH2PO4 andNa2HPO4, pH7.4, Sigma) for up to 14 days,with amedium
change every 3 days, as previously described [53]. The effects of gluco-
corticoids in FBS were assessed through comparison of charcoal-
stripped and standard FBS (Life Technologies Ltd). Cells were treated
with corticosterone (1–100 nM) (Sigma), 11-DHC (1–100 nM)
(Steraloids, Newport, USA), carbenoxolone (10 μM) (Sigma), dexa-
methasone (1–100 nM) (Sigma), mifepristone (10 μM) (Sigma) oreptor (MR). Effect of (A)mifepristone (10 μM) and (B) eplerenone (10 μM) in the presence
resence of 11-dehydrocorticosterone (11HDC; 100 nM) on calcium deposition in VSMCs
leaching (μg/mg protein) (n = 6). Results are presented as mean ± S.E.M. *P b 0.05;
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11-DHC used in the present study reﬂect those found in vivo. Plasma
corticosterone levels in mice range from 20 nM (nadir, morning) to
~150 nM (peak, evening) and stress levels are typically 200–250 nM.
Basal levels of plasma 11-DHC in mice have been reported at 2–5 nM
and stress levels N30 nM [12].2.4. Determination of VSMC calciﬁcation
Calciumdepositionwas quantiﬁed byHCl leaching, as describedpre-
viously [52]. Brieﬂy, cells were washed twice with phosphate buffered
saline (PBS) and incubated with 0.6 M HCl at room temperature for
24 h. Calcium content was determined colorometrically by a stable in-
teraction with phenolsulphonethalein using a commercially available
kit (Randox Laboratories Ltd., County Antrim, UK), corrected for total
protein concentration (Bio-Rad Laboratories Ltd., Hemel Hempstead,
UK), and presented as a fold change comparedwith control. Calciumde-
position was also evaluated by alizarin red staining. Cells were washed
twice with PBS, ﬁxed in 4% paraformaldehyde for 5 min at 4 °C, stained
with 2% alizarin red (pH 4.2) for 5 min at room temperature and rinsed
with distilled water.2.5. Analysis of gene expression
VSMCs were treated with corticosterone (Sigma) or 11-DHC
(Steraloids, Newport, USA), for 48 h in serum freeα-MEM (Invitrogen).
RNAwas extracted using RNeasy total RNA (Qiagen Ltd., Crawley, West
Sussex, UK), according to the manufacturer's instructions. RNA was
quantiﬁed and reverse transcribed as previously described [26]. Levels
of speciﬁc mRNAs were measured using the SYBR green detection
method (Roche, East Sussex, UK) as previously reported [42]. Primers
were obtained from Qiagen (sequences not disclosed) for PiT-1
(NM_001159593), Bmp2 (NM_007553) andMsx2 (NM_013601).2.6. Quantiﬁcation of apoptosis
On reaching conﬂuence, cells were serum starved for 24 h, then
treated with 100 nM corticosterone for 48 h. Cells were harvested by
trypsinization and re-suspended in 25 μl 1% trypan blue (diluted 50%
in PBS). Live cells, which exclude trypan blue and dead cells (stained
blue) were counted using a hemocytometer, and the results expressed
as the percentage of cells that were dead. Apoptotic VSMCs were deter-
mined by manually counting pyknotic nuclei after staining with DAPI
(Invitrogen) as previously described [9]. Additionally, cells in different
stages of apoptosis were analyzed by ﬂow cytometry using the TACS
Annexin-V-FITC apoptosis detection kit (R&D systems, Abingdon, UK),
according to the manufacturer's instructions. Non-apoptotic cells do
not stainwith either Annexin-V FITC or propidium iodide. Early apopto-
tic cells are stained with Annexin-V FITC but not propidium iodide
(green ﬂuorescence). Late apoptotic cells are stained with both
Annexin-V FITC and propidium iodide (dual green and red ﬂuores-
cence). Necrotic cells are only stained with propidium iodide (red ﬂuo-
rescence). 10,000 cell events were recorded on a BD FACS Calibur and
data were analyzed with FlowJo 8.8.4 ﬂow cytometry analysis software
(Tree Star Inc., Ashland, Oregon, USA).Fig. 3. Endogenous glucocorticoids do not induce osteogenicmarker expression in VSMCs.
Fold change in the mRNA expression of osteogenic markers (A) PiT-1, (B) Osx, and
(C) Bmp2 (n = 4) following treatment with corticosterone (white bar) and 11-
dehydrocorticosterone (11DHC; ﬁlled bar) (1–100 nM). 0 nM treatment expressed as 1
to indicate fold change for each gene of interest. Results are presented as mean ± S.E.M.
*P b 0.05; **P b 0.01; ***P b 0.001 compared with corresponding 0 nM treatment.2.7. Statistical analysis
General Linear Model analysis and the Students t-test were used to
assess the data. All data are expressed as the mean ± S.E.M. Statistical
analysis was performed using Minitab 16. P b 0.05 was considered to
be signiﬁcant.3. Results
3.1. Glucocorticoids facilitates VSMC calciﬁcation
We initially examined the effects of physiological glucocorticoids
on the calciﬁcation of VSMCs, with the synthetic glucocorticoid dexa-
methasone used as a positive control. Since arterial calciﬁcation is high-
ly correlated with elevated serum Pi levels, VSMCs were cultured in
growth medium containing high (3 mM) Pi as previously described
([53]; Zhu et al., 2016). Cells were treatedwith dexamethasone, cortico-
sterone or 11-DHC (1–100 nM) for up to 7 days. Dexamethasone treat-
ment signiﬁcantly increased calcium deposition of VSMCs (17.16 fold,
P b 0.05, Fig. 1A). Both corticosterone and 11-DHC signiﬁcantly in-
creased calcium deposition in VSMCs cultured with un-stripped FBS
(1.51 fold, P b 0.001 and 1.72 fold respectively, P b 0.001; Fig. 1B).
Surprisingly, 11-DHC was more potent than corticosterone, with a sig-
niﬁcant effect at 10 nM, compared to 100 nM for corticosterone. Using
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of both corticosterone and 11-DHC on VSMC calciﬁcation (7.98 fold,
P b 0.01 and 7.14 fold, P b 0.05 respectively; Fig. 1C). The 11β-HSD in-
hibitor carbenoxolone notably reduced 11-DHC-induced calciﬁcation
of VSMCS (0.37 fold compared to treatment with 11-DHC alone,
P b 0.001, Fig. 1D), conﬁrming the 11β-HSD isoenzymes as key regula-
tors of intracellular glucocorticoid levels [4].
3.2. Corticosterone and 11-DHC facilitate VSMC calciﬁcation through the
MR
In order to establish whether corticosterone acts via GR or MR to in-
duce VSMC calciﬁcation, antagonists of both MR (eplerenone) and GR
(mifepristone) were employed. Mifepristone (10 μM) itself potentiated
VSMC calciﬁcation, but did not alter the response to corticosterone
(Fig. 2A) or 11-DHC (Fig. 2B). However, eplerenone (10 μM) signiﬁcantly
attenuated the effect of corticosterone (0.81 fold compared to treatment
with corticosterone alone; P b 0.01) and 11-DHC (0.64 fold compared to
treatment with 11-DHC alone; P b 0.01) on VSMC calciﬁcation.
3.3. Corticosterone and 11-DHC induce VSMC apoptosis
Published data implicate the transdifferentiation of VSMCs to an
osteoblast-like phenotype as a mechanism underlying the effects of
dexamethasone upon vascular calciﬁcation [29]. We therefore next
tested whether the same is true for physiological glucocorticoids. Inter-
estingly, neither corticosterone nor 11-DHC alteredmRNA levels of key
osteogenicmarkers: PiT-1 (Fig. 3A),Osx (Fig. 3B) andBmp2 (Fig. 3C). Re-
cent reports have highlighted apoptosis as essential for the initiation
and progression of phosphate-induced vascular calciﬁcation [41].
Therefore we undertook a detailed assessment of apoptosis followingFig. 4. Endogenous glucocorticoids induce apoptosis in VSMCs. Effect of corticosterone (1–100n
apoptotic nuclei as determined by DAPI staining (%) and (E) Annexin V staining of isolated cells
***P b 0.001 compared with corresponding 0 nM treatment.glucocorticoid treatment. Corticosterone treatment signiﬁcantly re-
duced cell viability (2.07 fold; P b 0.01; Fig. 4A), and conversely in-
creased cell death (2.53 fold; P b 0.05; Fig. 4B) and apoptosis (Fig. 4C–
E) as determined by DAPI staining of pykrotic nuclei and FACS analysis
of cells positively stained for Annexin V.
4. Discussion
It is well established that glucocorticoids mediate changes in vas-
cular growth, function and structure [10]. Previous studies in VSMCs
have reported the pro-calciﬁcation effects of dexamethasone, a po-
tent synthetic glucocorticoid. Here we demonstrate for the ﬁrst
time the facilitation of vascular calciﬁcation by both the active phys-
iological glucocorticoid corticosterone and the inactive metabolite
11-DHC.
Currently 11β-HSD inhibition is therapeutically employed in topical
preparations for the management of mouth ulcers [14]. Furthermore,
11β-HSD-inhibition has been shown to correct insulin resistance in ro-
dentmodels of CKD, a hallmark of this disease in patients being vascular
calciﬁcation [2]. The in vitro experiments undertaken in this study
therefore identify 11β-HSD inhibition as a plausible treatment for vas-
cular calciﬁcation, and requires further interrogation in vivo.
Whilst VSMC calciﬁcation is facilitated by GR selective dexametha-
sone (Fig. 1; [29]), and macrophage-speciﬁc GR inactivation reduces
vascular calciﬁcation in a mouse model of atherosclerosis [34], the
pro-calciﬁcation effects of corticosterone and 11-DHC do not appear to
bemediated through GR signaling. Furthermore, whilst dexamethasone
has been previously reported to accelerate the osteogenic differentia-
tion of vascular pericytes [18] and bovine VSMCs [29], in the present
study Osterix, Bmp2 and PiT-1 expression were unaltered in VSMCs
treated with corticosterone or 11DHC. Interestingly, these data contrastM)on (A)Alamar blue uptake (OD570 nm–620 nm), (B) trypan blue uptake (%), (C andD)
as assessed by FACS analysis. Results are presented asmean± S.E.M. *P b 0.05; **P b 0.01;
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signaling [46]. This paradigm likely reﬂects different mechanisms un-
derpinning the calciﬁcation permitted by synthetic and physiological
glucocorticoids. Indeed, our studies suggest that the pro-calciﬁcation ef-
fects of corticosterone and 11-DHC are mediated directly through MR,
corroborating previouswork in VSMCs showing the activation ofMR sig-
naling by glucocorticoids [27]. Furthermore, our data complement previ-
ous work revealing that CVCs (calcifying vascular cells; subpopulations
of VSMCs which have been found to spontaneously calcify in vitro) con-
tainMRswhich function as transcriptional regulators that can be activat-
ed by both aldosterone and cortisol [15]. Indeed aldosterone
administration has been shown to directly stimulate CVC calciﬁcation,
an effect abolished by aldosterone antagonism with spironolactone
[15]. Moreover, vascular calciﬁcation facilitated by hyperaldosteronism
due to klotho deﬁciency has also been shown to be mitigated by
spironolactone treatment in mice [46]. Further studies are therefore re-
quired to directly compare the effects of aldosterone treatment on
VSMC calciﬁcation with that of corticosterone and 11-DHC.
The present study also highlights that the effect of corticosterone
and 11-DHC on driving VSMC calciﬁcation is more pronounced when
charcoal stripped media is used to remove endogenous steroid ligands,
suggesting an activating effect of endogenous MR ligands in normal,
unstripped serum. Thesedata support comparableﬁndings demonstrat-
ing that aldosterone-induced CVC calciﬁcation viaMR activation is also
enhanced using charcoal stripped serum [15].
Mechanistically, our data reveal that corticosterone reduces cell via-
bility and stimulates VSMC apoptosis. This process is essential for the
initiation and progression of phosphate-induced vascular calciﬁcation
[41], with apoptotic bodies exposing phosphatidylserine on the outer
membranes, generating a potential calcium-binding site suitable for hy-
droxyapatite deposition [35,40]. These results support previous reports
demonstrating that glucocorticoids inhibit VSMC proliferation [22,44]
and induce apoptosis in a range of cell types including neuronal cells,
growth plate chondrocytes and thymocytes [6,7,20,21].
In conclusion, we have undertaken in vitromurine VSMC studies to
provide new insights into the role of physiological glucocorticoids
in vascular calciﬁcation. Our study suggests that corticosterone acts
through the MR to induce pro-calciﬁcation effects. This data may have
important health ramiﬁcations for patients receiving MR blockers. The
previously established clinical cardiovascular beneﬁts of eplerenone ad-
ministration [33], in conjunctionwith our in vitro ﬁndingsmay pave the
way for pre-clinical and clinical trials for the treatment of vascular calci-
ﬁcation with eplerenone therapy. Inhibiting 11β-HSD isoenzymes and
subsequently diminishing vascular calciﬁcation may also represent a
novel potential pharmaceutical target for clinical intervention.
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